Compare Sumitomo Bakelite Co., Ltd. with Similar Stocks
Dashboard
1
Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 50.74
2
Low Debt Company with Strong Long Term Fundamental Strength
3
Flat results in Jun 25
4
With ROE of 6.72%, it has a very attractive valuation with a 1.27 Price to Book Value
5
Market Beating Performance
Stock DNA
Pharmaceuticals & Biotechnology
JPY 491,198 Million (Mid Cap)
19.00
NA
0.00%
-0.26
6.52%
1.59
Revenue and Profits:
Net Sales:
77,668 Million
(Quarterly Results - Jun 2025)
Net Profit:
7,517 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
9.5%
0%
9.5%
6 Months
16.14%
0%
16.14%
1 Year
54.47%
0%
54.47%
2 Years
40.87%
0%
40.87%
3 Years
32.17%
0%
32.17%
4 Years
-2.0%
0%
-2.0%
5 Years
34.3%
0%
34.3%
Sumitomo Bakelite Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
8.08%
EBIT Growth (5y)
16.54%
EBIT to Interest (avg)
50.74
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.25
Sales to Capital Employed (avg)
0.88
Tax Ratio
31.74%
Dividend Payout Ratio
45.47%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
12.76%
ROE (avg)
7.78%
Valuation key factors
Factor
Value
P/E Ratio
19
Industry P/E
Price to Book Value
1.27
EV to EBIT
9.60
EV to EBITDA
6.61
EV to Capital Employed
1.36
EV to Sales
0.97
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
14.16%
ROE (Latest)
6.72%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
Bearish
Bearish
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Bullish
Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
77,668.00
73,682.00
5.41%
Operating Profit (PBDIT) excl Other Income
12,455.00
10,454.00
19.14%
Interest
164.00
56.00
192.86%
Exceptional Items
0.00
0.00
Consolidate Net Profit
7,517.00
6,507.00
15.52%
Operating Profit Margin (Excl OI)
116.00%
94.00%
2.20%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 5.41% vs -5.48% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is 15.52% vs 3,941.61% in Mar 2025
Annual Results Snapshot (Consolidated) - Mar'25
Mar'25
Mar'24
Change(%)
Net Sales
304,773.00
287,267.00
6.09%
Operating Profit (PBDIT) excl Other Income
44,805.00
41,138.00
8.91%
Interest
333.00
322.00
3.42%
Exceptional Items
-5,517.00
0.00
Consolidate Net Profit
19,531.00
21,940.00
-10.98%
Operating Profit Margin (Excl OI)
101.20%
95.70%
0.55%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2025 is 6.09% vs 0.82% in Mar 2024
Consolidated Net Profit
YoY Growth in year ended Mar 2025 is -10.98% vs 6.53% in Mar 2024
About Sumitomo Bakelite Co., Ltd. 
Sumitomo Bakelite Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






